Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Incyte Corporation’s recent clinical study, officially titled ‘A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy – (FIGHT-202),’ aims to assess the efficacy of pemigatinib in patients with cholangiocarcinoma who have not responded to previous treatments. This study is significant as it targets a challenging cancer type with limited treatment options.
The intervention being tested is pemigatinib, an oral drug administered once daily for two weeks followed by a week off. It is designed to treat patients with specific genetic alterations related to FGFR2 translocations.
The study follows an interventional design with a non-randomized, parallel assignment model. There is no masking involved, and the primary purpose is treatment-focused, aiming to provide insights into the drug’s effectiveness and safety.
The study commenced on January 16, 2017, with primary results submitted in January 2023. The last update was recorded in August 2025, marking the study’s completion. These dates are crucial for tracking the study’s progress and understanding its timeline.
The update on this study could potentially impact Incyte Corporation’s stock performance positively, as successful results may enhance investor confidence and market position. The study’s outcomes could also influence the competitive landscape in the oncology sector, particularly for treatments targeting FGFR2 alterations.
The study is ongoing, with further details available on the ClinicalTrials portal.